Advertisement

Topics

Abcam plc Exercises Exclusivity Provision of License and Supply Agreement with Horizon Discovery

08:32 EDT 29 Jun 2017 | Zyme Communications

  • Abcam extends a pre-existing license and supply agreement with Horizon by exercising an exclusivity provision for the period from July 2017 through June 2018
  • Horizon’s knockout cell models have enabled Abcam to validate its antibody catalogue at an unprecedented scale
  • Reagent validation is an important component of efforts to improve reproducibility in medical research

Cambridge, UK, 29 June 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the “Group”), the world leader in the application of gene editing technologies, today announces that Abcam plc (AIM:ABC) (“Abcam”), a global leader in the supply of research antibodies, has extended a pre-existing license and supply agreement between the two companies by exercising an exclusivity provision for the period from July 2017 through June 2018.  

In September 2015, Horizon and Abcam entered into a collaboration to provide exclusive access to Horizon’s extensive library of human diploid and haploid cell line models for the functional validation of Abcam’s existing monoclonal and polyclonal antibodies, and for the development of additional haploid cell lines to validate new antibodies introduced by Abcam.

The validation of antibodies is an important effort for Abcam as there is a significant issue with the reproducibility of scientific studies.  In 2012, Dr. C. Glenn Begley, former global head of Hematology and Oncology Research at Amgen, published a paper in Nature1 describing an effort to reproduce the results of 53 cancer-related publications in top journals and found that only six of these papers could be replicated, with a lack of reagent validation being a significant contributor to the problem. 

Abcam has stated that it is important for reagent suppliers to do more to tackle these issues, and has, therefore, engaged in an active programme to validate a large portion of its catalogue, made possible through Horizon’s knockout (KO) cell models. Knockout validation involves using cells that do not make the target protein of interest, thereby providing a true negative control, an approach Abcam found was preferred by many researchers. 

Since starting its KO validation initiative in 2015, Abcam has now validated several hundred antibodies using Horizon’s cell lines. This ongoing programme is being conducted at an unprecedented scale and is central to Abcam’s commitment to improving the standards of antibody validation. Recently, the importance of the programme was recognised when Abcam won the ‘Most exciting antibody validation initiative’ at the CiteAb 2017 Antibody Awards.

Under the terms of the agreement, Horizon receives exclusivity payments totaling £660,000 (c$1,000,000) across the initial three-year term, with preferred pricing charged for any additional haploid cell lines developed. In addition, Horizon receives a royalty on the sale of any Abcam antibodies marketed using validation data derived from Horizon cell lines for a period of 10 years from the first date of sale.

Dr. Darrin Disley, Chief Executive Officer, Horizon Discovery, commented: “We are pleased that Abcam has chosen to extend its exclusivity period for the use of Horizon’s cell models for antibody validation for another year. Researchers increasingly expect critical reagents such as antibodies to provide a reliable foundation for their work, and we are delighted that Horizon’s deep gene editing experience, including CRISPR and rAAV, breadth of intellectual property, and proprietary methods for the generation of high-throughput, low-cost haploid cell models, is enabling Abcam to rapidly validate its catalogue at scale.”

1.     https://www.nature.com/nature/journal/v483/n7391/full/483531a.html

Glossary:

  • Antibody: a protein produced in the blood that fights diseases by attacking harmful foreign bodies such as bacteria
  • Cell engineering: the development of cell lines that reflect the genetics of disease found in real patients by use of gene editing
  • CRISPR: a gene editing technology that enables genomic modifications in a wide variety of organisms and tissues with high efficiency
  • Haploid: cells that have only a single copy of most or all genes in its genome
  • Knockout (KO): a cell line that has had the production of the product of a gene completely turned off
  • rAAV: a gene editing technology, exclusive to Horizon for non-therapeutic applications, which allows cells to be edited with extreme precision and virtually no risk of unforeseen errors

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by over 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

Zyme Communications (Trade and Regional Media) Katie Odgaard Tel: +44 (0)7787 502 947 Email: katie.odgaard@zymecommunications.com Horizon Discovery Group plc Darrin Disley, Chief Executive Officer Richard Vellacott, Chief Financial Officer Chris Claxton, VP Investor Relations Tel: +44 (0) 1223 655 580 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner Tel: +44 (0) 20 3709 5701 Email: horizon@consilium-comms.com NEXT ARTICLE

More From BioPortfolio on "Abcam plc Exercises Exclusivity Provision of License and Supply Agreement with Horizon Discovery "

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...